ArticleCentral-European journal of immunology2016
The role of VipAlbumin(®) as an immunostimulatory agent for controlling homeostasis and proliferation of lymphoid cells.
Article in Central-European journal of immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 12 citations in OpenAlex.
- Effect on the splenocyte function of weaned piglets induced by continuous lipopolysaccharide injections.Journal of veterinary research · 2024Article
- Interstitial lung disease in Indonesian adult with systemic sclerotic: A rare case.Annals of medicine and surgery (2012) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VipAlbumin(®) is a supplement from snakehead fish (Ophiocephalus striatus) which has high content of albumin that is very important to develop new cells. The aims of this study were to know the effect of VipAlbumin(®) to cell proliferation, expression level of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell, and immunocompetent cell cycle. Cell isolated from spleen of pathogen free mice were cultured in RPMI 1640 with 10% FBS, 1% Pen/Strep 10×, 2-Mercaptoetanol, anti-CD3 and LPS. The concentrations of VipAlbumin (®) used were 0 µg/ml; 0.33 µg/ml; 33.3 µg/ml; and 3333.3 µg/ml. The cell was incubated in CO2 5% incubator 37°C for 3 days for cell cycle and 5 days for proliferation analysis and cell expression. FACS analysis was done to know cell proliferation profile, status of cell, and cell cycle. Concentration 33.3 µg/ml and 3333.3 µg/ml significantly can increase cell proliferation and induce cell enter G2/M phase (p < 0.05) compared to control. VipAlbumin can significantly increase the relative number of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell (p < 0.05) compared to control. This study gives scientific evidence that VipAlbumin can be used as an immunostimulant which accelerates immunocompetent cells growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.